Unlocking the Secrets of Aging: The Telomere Breakthrough

Why hasn't the "cure" for aging been found? According to molecular geneticist Bill Andrews, it’s not a lack of science—it’s a broken system. In this episode, the man who helped discover the "cellular ride tickets" (telomeres) that dictate our lifespan explains why the current biotech model favors profits over cures. We dive into the Hayflick Limit, the discovery of Telomerase, and the $130 million road map to making the "Betty White Test"—reversing 85 to 25—a biological reality.

Bill Andrews is the Founder and CEO of Sierra Sciences and a legendary molecular geneticist. With a career defined by "curing over publishing," Bill has been a key inventor for breakthrough therapies including Human Growth Hormone, Rytelo (cancer), and treatments for Multiple Sclerosis. He is one of the world’s leading experts on telomere biology and is famously obsessed with one goal: curing death by old age.

• The "Ride Ticket" Theory: Our cells have a finite number of divisions (The Hayflick Limit). Every time a cell divides, the telomeres (caps on our chromosomes) shorten until the "tickets" run out.
• The Telomerase Secret: Our reproductive cells don't age because they produce telomerase, an enzyme that adds "tickets" back to the chromosomes. Bill’s mission is to trigger this in all human cells.
• The System is Broken: Academic research is trapped in a "publish or perish" cycle, while biotech is often throttled by investors seeking quick ROI rather than long-term cures.
• The $130M Milestone: Bill estimates that with $130 million and three years of focused research, we could effectively cure human aging.
• Proof in Pets: Breakthroughs are already happening in the veterinary world with products designed to extend the lifespan of dogs, cats, and horses.

Enjoyed this deep dive into the future of medicine? Let’s keep the conversation going:

Bill Andrews: https://www.linkedin.com/in/william-h-andrews-ceo-5455b45/

Keith Willis:https://www.linkedin.com/in/keithawillis/

Why hasn't the "cure" for aging been found? According to molecular geneticist Bill Andrews, it’s not a lack of science—it’s a broken system. In this episode, the man who helped discover the "cellular ride tickets" (telomeres) that dictate our lifespan explains why the current biotech model favors profits over cures. We dive into the Hayflick Limit, the discovery of Telomerase, and the $130 million road map to making the "Betty White Test"—reversing 85 to 25—a biological reality.

Bill Andrews is the Founder and CEO of Sierra Sciences and a legendary molecular geneticist. With a career defined by "curing over publishing," Bill has been a key inventor for breakthrough therapies including Human Growth Hormone, Rytelo (cancer), and treatments for Multiple Sclerosis. He is one of the world’s leading experts on telomere biology and is famously obsessed with one goal: curing death by old age.

• The "Ride Ticket" Theory: Our cells have a finite number of divisions (The Hayflick Limit). Every time a cell divides, the telomeres (caps on our chromosomes) shorten until the "tickets" run out.
• The Telomerase Secret: Our reproductive cells don't age because they produce telomerase, an enzyme that adds "tickets" back to the chromosomes. Bill’s mission is to trigger this in all human cells.
• The System is Broken: Academic research is trapped in a "publish or perish" cycle, while biotech is often throttled by investors seeking quick ROI rather than long-term cures.
• The $130M Milestone: Bill estimates that with $130 million and three years of focused research, we could effectively cure human aging.
• Proof in Pets: Breakthroughs are already happening in the veterinary world with products designed to extend the lifespan of dogs, cats, and horses.

Enjoyed this deep dive into the future of medicine? Let’s keep the conversation going:

Bill Andrews: https://www.linkedin.com/in/william-h-andrews-ceo-5455b45/

Keith Willis:https://www.linkedin.com/in/keithawillis/

In Episode 3 of Inside Pharma Leadership, I sit down with Dr. Angela Tran, CEO & Founder of MedFit Medical Weight Loss, to talk about physician burnout, redefining how medicine is practiced, and what it really takes to achieve long-term, sustainable health.

Dr. Tran shares her journey from burnout in traditional healthcare to building a practice centered on “medical fitness”—helping patients not just lose weight, but transform their lifestyle, reduce medications, and take ownership of their health.

We also explore GLP-1 medications, wearable health tech, AI in medicine, and why mindset and support systems are often more important than diet and exercise alone.

Dr. Angela Tran is a board-certified physician, entrepreneur, and the CEO & Founder of MedFit Medical Weight Loss, which she launched in 2012.

After experiencing severe burnout in traditional primary care, Dr. Tran made the decision to redefine how she practiced medicine—focusing on prevention, lifestyle transformation, and long-term patient outcomes.

She specializes in obesity medicine and medical weight loss, helping patients reduce or eliminate medications while improving overall health. Her work combines clinical expertise, personal experience, and a strong emphasis on behavior, mindset, and accountability.

1. Physician Burnout Is Real—and Can Lead to Reinvention
Dr. Tran openly shares her experience with burnout and how it pushed her to leave traditional healthcare and build a practice aligned with her values and purpose.

2. Weight Loss Is More Than Diet and Exercise
Sustainable weight loss starts with mindset. Beliefs, habits, and support systems play a critical role in long-term success.

3. GLP-1 Medications Are Transformational—When Used Correctly
GLP-1s are changing the landscape of obesity and chronic disease treatment, but outcomes depend heavily on proper guidance and experienced providers.

4. Data and Wearable Tech Empower Patients
Tools like continuous glucose monitors and fitness trackers provide objective data that help patients take control of their health and make better decisions.

5. AI Enhances—Not Replaces—Healthcare
AI can provide speed, objectivity, and better decision support, but it works best when combined with human expertise and patient relationships.

6. The Right Support System Is Everything
Long-term success isn’t just about knowledge—it’s about having the right people around you, from providers to family and community support.

• Instagram: @medfitdrtran
• Email: [email protected]
• LinkedIn: https://www.linkedin.com/in/drtrangela/

• Email: [email protected]  
• LinkedIn: www.linkedin.com/in/keithawillis/ 

In Episode 2 of Inside Pharma Leadership, I sit down with Lorrinda Gray-Davis to talk about the intersection of patient experience, healthcare policy, and innovation.

Lorrinda shares how her personal journey through end-stage liver disease reshaped her career and led her into transplant advocacy, policy leadership, and building practical tools that help patients navigate access to medications and long-term care.

Our conversation explores what healthcare leaders often miss about patient access, the critical role of care partners, and how emerging technologies like AI can help simplify complex healthcare systems.

Meet the Guest

Lorrinda Gray-Davis is a transplant advocate, speaker, and policy leader focused on improving patient access to care and medication affordability.

Before entering healthcare advocacy, she spent more than 20 years in construction leadership, managing large-scale projects and leading teams across complex environments. After being diagnosed with end-stage liver disease, her experience navigating the healthcare system inspired her to dedicate her work to helping patients better understand and access the care they need.

Today she is actively involved in transplant advocacy and policy work through Transplant Recipients International Organization, while also developing tools designed to help patients navigate medication access and healthcare systems more effectively.

Key Takeaways

1. Healthcare Navigation Is Harder Than It Should Be

Many patients enter the healthcare system without clear guidance. Lorrinda compares it to going on a safari without a guide—patients are expected to navigate complex systems while dealing with serious health challenges.

2. Access to Medication Is Still a Major Challenge

From step therapy policies to insurance barriers, patients often struggle to access the medications they need. Education around copay cards, grants, and assistance programs can significantly reduce out-of-pocket costs.

3. Care Partners Are Critical to Patient Outcomes

Lorrinda emphasizes the importance of involving “care partners” in medical conversations. These individuals often play a key role in helping patients understand treatment options and advocate for their care.

4. Technology Can Help Simplify Patient Access

Lorrinda built the Transplant Medication Navigator to help patients identify financial assistance, copay programs, and insurance options in one centralized place.

5. AI Is a Tool for Amplifying Human Thinking

Rather than replacing jobs, AI can serve as a thinking partner—helping leaders, innovators, and advocates build better tools and systems when paired with critical thinking.

Connect with Lorrinda

• Website: lorrindagraydavis.com
• Transplant Medication Navigator: transplantmedicationnavigator.com
• Organization: Transplant Recipients International Organization
• LinkedIn: www.linkedin.com/in/lorrinda-gray-davis/

Connect with Keith

• Email: [email protected]  
• LinkedIn: www.linkedin.com/in/keithawillis/

The opioid crisis is the worst healthcare disaster in American history, yet for millions suffering from chronic pain, the only options are addiction or agony. What does it take to build a "Holy Grail" solution when there is no playbook? Steven Fox, a "rare kind of builder," joins us to discuss the high-stakes world of life science innovation, the art of surrounding yourself with "survivors," and why he believes he’s finally found the key to ending the opioid epidemic.

In this episode, Keith Willis sits down with Steven Fox, Chairman and Founder of Akelos Incorporated. From his roots as a cosmetic dentist to becoming an Ernst & Young Entrepreneur of the Year, Steven shares his 40-year journey of turning big ideas into public ventures.

The conversation dives deep into the "three-dimensional chess" of biotech leadership: navigating the NIH grant system, building a world-class team of Nobel laureates without using headhunters, and the relentless tenacity required to move a non-opioid pain treatment toward FDA approval. Whether you are an aspiring entrepreneur or a seasoned executive, Steven’s "guerrilla warfare" approach to leadership offers a masterclass in survival and execution.

Steven Fox is the Chairman and Founder of Akelos Inc., a biopharmaceutical company dedicated to solving the opioid crisis through non-addictive chronic pain treatments. A dentist by trade and a lifelong entrepreneur, Steven has:

• Developed 68 patents and raised over $75 million in capital.
• Taken a technology from the ADA public and placed products in 42,000 stores across America.
• Been awarded the Ernst & Young Entrepreneur of the Year and the Medal of Freedom from members of the U.S. Senate.
• Assembled a powerhouse team featuring former heads of neuroscience from Merck, Pfizer, and Eli Lilly, alongside Nobel Prize winners.

• The "Survival" Team: Why "jockeys" are just as important as the "horse," and why Steven prefers team members seasoned in survival over S&P 500 pedigree.
• Bridging the Gap: How 48 years of treating dental pain provided the clinical insight needed to tackle the global opioid crisis.
• Entrepreneurial Tenacity: The reality of the 5 AM to 9 PM grind and why you have to be willing to "get up off the mat" repeatedly.
• The Patent Moat: The strategic (and sometimes costly) art of building intellectual property protection around groundbreaking science.
• Remaining "Sensationally Curious": Steven’s #1 piece of advice for anyone looking to innovate in a crowded marketplace.

• Email: [email protected] 
• LinkedIn: www.linkedin.com/in/drstevefox/

• Email: [email protected]  
• LinkedIn: www.linkedin.com/in/keithawillis/